6533b7d9fe1ef96bd126d717
RESEARCH PRODUCT
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
Vincenza CalvarusoCiro CelsaRoberta D'ambrosioFabio SimoneSalvatore PettaIrene CacciolaMarco EneaSalvatore BattagliaAlessandra PandolfoMassimo LicataElisabetta DegasperiGiuseppe CabibboLorenza Di MarcoGrazia PennisiMarta BorghiVincenzo Di MartinoRoberto FilomiaYasmin Abdel-hadiLuciano CrapanzanoGiovanni RaimondoPietro LamperticoAntonio CraxìCalogero CammàVito Di Marcosubject
Antiviral AgentMaleLiver CirrhosisHepatologyPlatelet CountLiver CirrhosiGastroenterologyHepacivirusHepatitis C ChronicEsophageal and Gastric VaricesAntiviral AgentsElasticity Imaging Techniques.Esophageal and Gastric VariceHumansElasticity Imaging TechniquesFemaleSerum AlbuminHumanAgeddescription
Noninvasive criteria to predict the progression of low-risk esophageal varices (EV) in patients with compensated hepatitis C virus (HCV) cirrhosis after sustained virological response (SVR) by direct-acting antivirals (DAAs) are lacking. Our aim was to assess the diagnostic performance of Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) criteria for EV progression compared with elastography-based criteria (Baveno VI, Expanded Baveno VI, and Baveno VII-HCV criteria).All consecutive patients observed at 3 referral centers with compensated HCV cirrhosis with or without F1 EV who achieved sustained virological response by DAAs were classified at last esophagogastroduodenoscopy (EGDS) as RESIST-HCV low risk (i.e., low probability of high-risk varices [HRV]) if platelets were120 × 10 9 /L and serum albumin3.6 g/dL or RESIST-HCV high risk (i.e., high probability of HRV) if platelets were120 × 10 9 /L or serum albumin3.6 g/dL. The primary outcome was the progression to HRV. The area under the receiver operating characteristic curve and decision curve analysis of noninvasive criteria were calculated.The cohort consisted of 353 patients in Child-Pugh class A (mean age 67.2 years, 53.8% males). During a mean follow-up of 44.2 months, 34 patients (9.6%, 95% CI 6.7%-13.5%) developed HRV. At the last EGDS, 178 patients (50.4%) were RESIST-low risk, and 175 (49.6%) were RESIST-high risk. RESIST-HCV criteria showed the highest area under the receiver operating characteristic curve (0.70, 95% confidence interval 0.65-0.75), correctly sparing the highest number of EGDS (54.3%), with the lowest false-positive rate (45.7%), compared with elastography-based criteria. Decision curve analysis showed that RESIST-HCV had higher clinical utility than elastography-based criteria.Biochemical-based RESIST-HCV criteria are useful to easily predict HRV development after HCV eradication by DAAs in patients with compensated cirrhosis and low-risk EV.
year | journal | country | edition | language |
---|---|---|---|---|
2022-01-18 | The American journal of gastroenterology |